Fibronectin based scaffold proteins having improved stability

Patent metadata

Field	Value
Publication number	US-9562089-B2
Application number	US-201113699458-A
Country	US
Kind code	B2
Filing date	May 26, 2011
Priority date	May 26, 2010
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.

First claim

The invention claimed is:

1. A polypeptide comprising an amino acid sequence having the structure:
N1-D1-C1-L-N2-D2-C2,
wherein N1 and N2 are optional N-terminal extensions independently comprising from 0-10 amino acids;
wherein D1 and D2 are independently selected from the group consisting of: (i) a tenth fibronectin type III domain ( 10 Fn3) domain having at least 95% identity with the amino acid sequence set forth in SEQ ID NO: 2, wherein said 10 Fn3 domain binds to insulin-like growth factor 1 receptor (IGF-1R) with a K D of less than 500 nM, and (ii) a 10 Fn3 domain having at least 95% identity with the amino acid sequence set forth in SEQ ID NO: 3, wherein said 10 Fn3 domain binds to vascular endothelial growth factor receptor 2 (VEGFR2) with a K D of less than 500 nM;
wherein L is a polypeptide linker comprising from 0-30 amino acid residues;
wherein C1 comprises the amino acid sequence of SEQ ID NO: 4; and wherein C2 comprises the amino acid sequence of SEQ ID NO: 4, 5 or 6.

2. A polypeptide comprising the amino acid sequence of SEQ ID NO: 25.

3. A fibronectin-based protein dimer comprising a first fibronectin type III tenth ( 10 Fn3) domain and a second 10 Fn3 domain, wherein each of the first 10 Fn3 domain and the second 10 Fn3 domain:
(a) comprises an AB loop, a BC loop, a CD loop, a DE loop, an EF loop, and an FG loop, wherein the first and second 10 Fn3 domains have at least one loop selected from the BC, DE, and FG loops with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain having the sequence of SEQ ID NO: 1, and
(b) comprises an amino acid sequence having at least 60% identity to SEQ ID NO: 1 and binds to a target molecule with a K D of less than 100 nM,

wherein one of the first and second 10 Fn3 domains comprises a C-terminal tail which comprises the amino acid sequence of SEQ ID NO: 4 and does not contain the amino acid sequence DK and the other 10 Fn3 domain comprises a C-terminal tail which comprises the amino acid sequence of SEQ ID NO: 33, and wherein the protein dimer comprises an amino acid sequence at least 90% identical to SEQ ID NO: 25.

4. The protein dimer of claim 3 , wherein the protein dimer comprises an amino acid sequence at least 95% identical to SEQ ID NO: 25.

5. The protein dimer of claim 3 , wherein each of the first 10 Fn3 domain and the second 10 Fn3 domain further comprises an N-terminal extension comprising from 1-10 amino acids.

6. The polypeptide or protein dimer of claim 1 , 2 , or 3 , further comprising one or more pharmacokinetic (PK) moieties selected from: a polyoxyalkylene moiety, a human serum albumin binding protein, sialic acid, human serum albumin, transferrin, and an Fc fragment.

7. A pharmaceutical composition comprising the polypeptide or protein dimer of claim 1 , 2 , or 3 .

8. A nucleic acid encoding the polypeptide or protein dimer of claim 1 , 2 , or 3 .

9. A vector comprising the nucleic acid of claim 8 .

10. A host cell comprising the nucleic acid of claim 8 .

11. The polypeptide of claim 1 or 3 , wherein the first and second 10 Fn3 domains are connected by a polypeptide linker selected from the group consisting of: a glycine serine based linker, a glycine proline based linker, a proline alanine linker and an Fn based linker.

12. The polypeptide of claim 11 , wherein the polypeptide linker comprises the amino acid sequence of SEQ ID NO: 9.

13. The polypeptide or protein dimer of claim 1 or 3 , wherein the C-terminal tail of one or both of the first 10 Fn3 domain and the second 10 Fn3 domain further comprises a cysteine residue.

14. The protein dimer of claim 1 or 3 , wherein the C-terminal tail of both the first 10 Fn3 domain and the second 10 Fn3 domain comprises the amino acid sequence of SEQ ID NO: 33.

Assignees

• Camphausen Ray
• O'Loughlin John
• Yeung Bernice
• Zhang Yihong
• Bristol Myers Squibb Co

Inventors

• Camphausen Ray
• O'Loughlin John
• Yeung Bernice
• Zhang Yihong

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07K14/78 Primary

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title